Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
InChi: InChI=1S/C20H30N2O5/c1-20(2
PubMed PMID: 22388233
3-benzoxazol-2-one
PubMed PMID: 26952246
Currently a phase I study of MEK162 in patients with biliary tract cancer is undergoing
Oclacitinib - CAS# 1208319-26-9 Catalog No.:M9848-2 InChi: InChI=1S/C20H30N2O5/c1-20(2Oclacitinib, also known as PF03394197, is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Oclacitinib inhibited JAK family members by 50% at concentrations (IC50 's) ranging from 10 to 99 nM and did not inhibit a panel of 38 non JAK kinases (IC50 's > 1000 nm). Oclacitinib was most potent at inhibiting JAK1 (IC50 = 10 nm). Oclacitinib also inhibited the function of JAK1 dependent cytokines involved in allergy and
US$ 3622.56
Sold : Login>>